Michael Pham, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1194735019
Payments from drug & device makers
What this record shows
27 manufacturers reported payments, led by Abbott at 37.8% of the total. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 142 payments — averaging $64.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$1K
- Edwards Lifesciences$1K
- Amgen$765
- Novartis$404
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$372
- plus $1K from 21 others
Across 17 payments — averaging $6854.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$72K
- AstraZeneca$34K
- Biocardia, Inc.$10K
What the payments were for
- Travel & lodging$3,92743%
- Food & beverage$5,20057%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 51 | $3,452 |
| Abiomed | 8 | $1,485 |
| Edwards Lifesciences | 6 | $1,366 |
| Amgen | 14 | $765 |
| Novartis | 4 | $404 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $372 |
| Impulse Dynamics (USA) Inc. | 1 | $129 |
| AstraZeneca | 5 | $106 |
| Boston Scientific | 6 | $96 |
| Johnson & Johnson | 6 | $94 |
| AbbVie | 3 | $81 |
| Heartflow, Inc. | 2 | $76 |
| Irhythm Technologies, Inc. | 3 | $75 |
| Alnylam Pharmaceuticals Inc. | 3 | $74 |
| Pfizer | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $60 |
| Teleflex LLC | 1 | $60 |
| Boehringer Ingelheim | 3 | $50 |
| Paragonix Technologies, Inc. | 1 | $44 |
| Astellas Pharma US Inc | 2 | $39 |
| Novo Nordisk | 1 | $32 |
| Cvrx, Inc. | 1 | $32 |
| One Lambda, Inc. | 1 | $29 |
| Cathworks, Inc. | 1 | $26 |
| Gilead | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,126 in reported general payments places this provider in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 45 | $1,295,618 |
| VyndaqelTafamidis Meglumine | 25 | $577,844 |
| EntrestoSacubitril/Valsartan | 128 | $182,722 |
| FarxigaDapagliflozin Propanediol | 80 | $95,588 |
| EliquisApixaban | 71 | $81,659 |
| JardianceEmpagliflozin | 43 | $57,672 |
| XareltoRivaroxaban | 17 | $13,885 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,535 |
| Bumetanide | 67 | $3,769 |
| Eplerenone | 29 | $2,132 |
| Amiodarone Hcl | 27 | $1,518 |
| Carvedilol | 132 | $797 |
| Rosuvastatin Calcium | 42 | $768 |
| Metoprolol Succinate | 45 | $733 |
| Atorvastatin Calcium | 111 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $70 | $1,955,120141 claims |
| NovartisEntresto | $404 | $182,722128 claims |
| AstraZenecaFarxiga | $106 | $95,58880 claims |
| Boehringer IngelheimJardiance | $50 | $57,67243 claims |
| Johnson & JohnsonXarelto | $94 | $13,88517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Francisco
- Teresa de MarcoSan Francisco$366K
- Liviu KleinSan Francisco$223K
- Marc SimonSan Francisco$114K
- Michael MartynSan Francisco$89K
- Shweta MotiwalaSan Francisco$50K
- Mandar ArasSan Francisco$41K
- Jared HerrSan Francisco$12K
- Pooja PrasadSan Francisco$8K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.